Combination therapy to prevent cardiovascular disease: Slow progress

JAMA

Volumn 309, Issue 15, 2013, Pages 1595-1596

  Smith, Richard ^a   McCready, Tara ^b   Yusuf, Salim ^b  

^a United Health Chronic Disease Initiative   (United Kingdom)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DRUG APPROVAL; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; HUMAN; LICENSING; PHYSICIAN ATTITUDE; POLYPHARMACY; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; SHORT SURVEY; ARTICLE; CLINICAL PRACTICE; COST CONTROL; DRUG COMBINATION; DRUG INDUSTRY; MASS SCREENING; PATIENT COMPLIANCE; TREATMENT OUTCOME;

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; COST CONTROL; DRUG COMBINATIONS; DRUG COSTS; DRUG INDUSTRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MASS SCREENING; MEDICATION ADHERENCE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; SECONDARY PREVENTION; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84876337781     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.3180     Document Type: Short Survey

References (8)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-2128.
2. Yusuf S, Islam S, Chow CK, et al Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798): 1231-1243.
3. Diaz R, Ertl G; European Society of Cardiology Congress. PURE: Prevalence, awareness, treatment and control of hypertension in 600 urban and rural communities from 17 high, middle and low income countries: results from the PURE (Prospective Urban Rural Epidemiology). 2012. http://www.escardio.org/ congresses/esc-2012/congress-reports/Pages/709-1-PURE.aspx#.UUpL5Rzvu8B. Published August 26, 2012. Accessed March 20, 2013.
4. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147-1152. (Pubitemid 40720739)
5. Elley CR, Gupta AK, Webster R, et al. The efficacy and tolerability of "polypills": meta-analysis of randomised controlled trials. PLoS One. 2012;7(12):e52145.
6. American Heart Association. People more likely to take heart medicines in combo pill: American Heart Association late-breaking clinical trials report. http://newsroom.heart.org/news/people-more-likely-to-take-heart-240422. Published November 5, 2012. Accessed January 25, 2013.
7. The Global Summit on Combination Polypharmacy for Cardiovascular Disease, September 2012, Hamilton, Ontario, Canada. http://www.cannectin.ca/default.cfm? id=147. Accessed March 19, 2013.
8. Dudl RJ, Wang MC, Wong M, Bellows J. Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications. Am JManag Care. 2009;15(10):e88-e94.